Authors
Daniel M Beswick, Christine M Liu, Jonathan B Overdevest, Anna Zemke, Aastha Khatiwada, David A Gudis, Jessa E Miller, Adam Kimple, Jeremy P Tervo, Emily DiMango, Jennifer L Goralski, Claire Keating, Brent Senior, Amanda L Stapleton, Patricia H Eshaghian, Jess C Mace, Karolin Markarian, Jeremiah A Alt, Todd E Bodner, Naweed I Chowdhury, Anne E Getz, Peter H Hwang, Ashoke Khanwalker, Jivianne T Lee, Douglas A Li, Meghan Norris, Jayakar V Nayak, Cameran Owens, Zara M Patel, Katie Poch, Rodney J Schlosser, Kristine A Smith, Timothy L Smith, Zachary M Soler, Jeffrey D Suh, Grant A Turner, Marilene B Wang, Milene T Saavedra, Jennifer L Taylor Cousar
Publication date
2024/4/18
Journal
The Laryngoscope
Publisher
John Wiley & Sons, Inc.
Description
Objectives
The 22‐question SinoNasal Outcome Test (SNOT‐22) assesses chronic rhinosinusitis (CRS) severity. We aimed to identify predictors of SNOT‐22 score improvement following highly effective modulator therapy (HEMT) initiation and to corroborate the SNOT‐22 minimal clinically important difference (MCID) in adults with cystic fibrosis (CF).
Methods
Prospective observational data was pooled from four studies across 10 US centers investigating people with CF (PwCF) and CRS. Three studies evaluated HEMT's impact on CRS. For participants enrolled prior to HEMT initiation, SNOT‐22 scores were obtained at baseline and after 3–6 months of HEMT. Multivariate regression identified predictors of improvement. Cronbach's alpha and four distribution‐based methods were used to assess internal consistency and calculate the MCID of the SNOT‐22.
Results
A total of 184 PwCF participated with mean …
Total citations
20242
Scholar articles
DM Beswick, CM Liu, JB Overdevest, A Zemke… - The Laryngoscope, 2024